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Background: Infection with the apicomplexan protozoan parasite T. gondii can cause severe and potentially fatal cer‑
ebral and ocular disease, especially in immunocompromised individuals. The anticoccidial ionophore drug monensin 
has been shown to have anti‑Toxoplasma gondii properties. However, the comprehensive molecular mechanisms that 
underlie the effect of monensin on T. gondii are still largely unknown. We hypothesized that analysis of T. gondii tran‑
scriptional changes induced by monensin treatment can reveal new aspects of the mechanism of action of monensin 
against T. gondii.
Methods: Porcine kidney (PK)‑15 cells were infected with tachyzoites of T. gondii RH strain. Three hours post‑infec‑
tion, PK‑15 cells were treated with 0.1 μM monensin, while control cells were treated with medium only. PK‑15 cells 
containing intracellular tachyzoites were harvested at 6 and 24 h post‑treatment, and the transcriptomic profiles of T. 
gondii‑infected PK‑15 cells were examined using high‑throughput RNA sequencing (RNA‑seq). Quantitative real‑time 
PCR was used to verify the expression of 15 differentially expressed genes (DEGs) identified by RNA‑seq analysis.
Results: A total of 4868 downregulated genes and three upregulated genes were identified in monensin‑treated 
T. gondii, indicating that most of T. gondii genes were suppressed by monensin. Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway enrichment analysis of T. gondii DEGs showed that T. gondii metabolic and cellular path‑
ways were significantly downregulated. Spliceosome, ribosome, and protein processing in endoplasmic reticulum 
were the top three most significantly enriched pathways out of the 30 highly enriched pathways detected in T. gondii. 
This result suggests that monensin, via down‑regulation of protein biosynthesis in T. gondii, can limit the parasite 
growth and proliferation.
Conclusions: Our findings provide a comprehensive insight into T. gondii genes and pathways with altered expres‑
sion following monensin treatment. These data can be further explored to achieve better understanding of the 
specific mechanism of action of monensin against T. gondii.
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Background
Toxoplasma gondii is one of the most successful oppor-
tunistic pathogens and has a wide range of intermediate 
hosts [1, 2]. This prolific parasite is estimated to cause 
latent infection in a third of the global human population 
[3]. While T. gondii is largely benign in immunocompe-
tent individuals, infection with this parasite can cause 
severe inflammation of the retina, and in severely immu-
nosuppressed patients, latent tissue cysts can reactivate 
in the brain causing life-threatening toxoplasmic enceph-
alitis [4]. Toxoplasma gondii is also responsible for signif-
icant economic losses attributed to abortions of pregnant 
sheep following primary infection especially during early 
and mid-pregnancy [5].
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In veterinary medicine, control of ovine toxoplasmo-
sis relies on the use of decoquinate [6]. Also, monen-
sin [7] and the folate inhibitor drugs, sulphamezathine 
and pyrimethamine [8], have been evaluated against T. 
gondii infection in pregnant sheep. There is a vaccine 
 (Toxovax®, MSD Animal health) licensed for the preven-
tion of abortion in sheep [9], although this vaccine suffers 
from a number of shortcomings [10]. Regarding humans, 
the first-line therapy for T. gondii infection is a combi-
nation of pyrimethamine and sulfadiazine. However, this 
regimen has some limitations because these drugs must 
be taken for a long duration, often cause side effects, and 
are incapable of eliminating the latent infection [11]. 
These drawbacks pose a major obstacle in conventional 
chemotherapy of toxoplasmosis in humans. To this end, 
efforts have been made to identify new and more effec-
tive medicines [12, 13] and to understand the mechanism 
of action [14] and perturbation associated with the cur-
rently used drugs [15].
One of the drugs that received more attention in recent 
years is monensin, which is an ionophore antibiotic used 
to treat coccidiosis in poultry and dairy animals. Mon-
ensin has shown antiparasitic activity against T. gondii 
in  vitro [16, 17] and in sheep [7]. Through induction of 
oxidative stress, monensin disrupts the mitochondrial 
function, and induces an arrest of the cell cycle and 
autophagy-like cell death in T. gondii [14]. Given the 
promising anti-T. gondii activity of monensin, further 
understanding of its mechanism of action could reveal 
new targets for drug development against T. gondii. The 
transcriptomic profile of T. gondii-infected porcine kid-
ney (PK-15) cells has been reported [18]. However, com-
prehensive understanding of how monensin treatment 
alters the transcriptome of T. gondii remains unknown.
In the present study, we profiled global gene expres-
sion in T. gondii following treatment of T. gondii-infected 
PK-15 cells with monensin using high-throughput 
RNA-sequencing (RNA-seq) analysis. Our data showed 
that monensin can cause genome-wide transcriptional 
changes in T. gondii.
Methods
Toxoplasma gondii culture
Tachyzoites of T. gondii RH strain were cultured and 
maintained in porcine (Sus scrofa) kidney (PK-15) cell 
monolayers. PK-15 cells were obtained from the Ameri-
can Tissue Culture Collection (ATCC ® CCL-33™; Mary-
land, USA) and cultured in Dulbecco’s Modified Eagleʼs 
Medium (DMEM, HyClone, Shanghai, China) supple-
mented with 10% fetal bovine serum (Gibco, Maryland, 
USA) at 37 °C in 5%  CO2. Tachyzoites were harvested 
when 80% of the infected PK-15 cells had lysed. The 
infected cells and egressed tachyzoites were passed 
through a 22-gauge needle 20 times to rupture any 
remaining PK-15 cells. The supernatant was removed by 
centrifugation at 350×g for 10 min at 4 °C, and the tachy-
zoites were resuspended in 3 ml DMEM. The final puri-
fied tachyzoites were counted using a hemocytometer.
Monensin treatment
PK-15 cells were infected with tachyzoites at a multiplic-
ity of infection of 3 (3 tachyzoites: 1 PK-15 cell). Three 
hours post-infection, 12 T25 tissue culture flasks were 
randomly divided into four groups (3 flasks/group). The 
two treatment groups included M6 (T. gondii-infected 
cells at 6 h post-monensin treatment) and M24 (T. gon-
dii-infected cells at 24 h post-monensin treatment). 
The two control groups (C6 and C24) were infected and 
untreated cells. The M6 and M24 groups were treated 
with monensin solution (Alfa Aesar, Ward Hill, USA) at 
a final concentration of 0.1 μM, while the control groups 
were treated with fresh medium without monensin. Each 
group included three biological replicates. The treated 
and control (untreated) cells were harvested at 6 and 24 
h post-treatment and stored at -80 °C, until used for RNA 
extraction and RNA-seq.
RNA extraction and RNA‑seq analysis
Total RNA was individually extracted from each sam-
ple using TRIzol (Invitrogen China Ltd, Beijing, China) 
according to the manufacturer’s instructions. All 
extracted RNAs were treated with RNase-Free DNase 
(Ambion, Shanghai, China) to remove any residual 
genomic DNA. The integrity and quantity of all RNA 
samples were examined using the Agilent 2100 Bioana-
lyzer (Agilent Technologies, Santa Clara, CA, USA) and 
a  NanoDropTM spectrophotometer (Thermo Scientific, 
Wilmington, DE, USA), respectively. Five micrograms 
of total RNA were used for the construction of the tran-
scriptome libraries and 100-bp paired-end strand-specific 
RNA-sequencing was performed on the BGISEQ-500 
Platform as per the manufacturer’s instructions.
Sequence filtering, read mapping and analysis 
of differentially expressed genes (DEGs)
The raw sequencing data were processed using the 
FASTX tool (http://hanno nlab.cshl.edu/fastx _toolk it/) 
to remove adaptor sequences, low-quality reads (qual-
ity value < 20), reads containing > 5% N rate and joint 
sequences before downstream analyses. StringTie [19] 
was used to reconstruct the transcripts guided by the 
genomic annotation information. Novel transcripts 
were identified using Cuffcompare (a tool of Cufflinks) 
[20]. The coding ability of new transcripts was pre-
dicted using Coding Potential Calculator [21]. The high-
quality clean reads were then mapped to the reference 
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genomes of pig (Sus scrofa) (ftp://ftp.ncbi.nlm.nih.gov/
genom es/Sus_scrof a/) and T. gondii (ftp://ftp.ncbi.nlm.
nih.gov/genom es/refse q/proto zoa/Toxop lasma _gondi 
i/lates t_assem bly_versi ons/GCF_00000 6565.2_TGA4) 
using HISAT and Bowtie 2 tools [22]. The gene expres-
sion level was calculated for each sample using the RSEM 
(RNA-seq by expectation-maximization) program [23] 
and the FPKM (fragments per kilobase of exon per mil-
lion mapped fragments) method. DEseq2 software was 
used to identify the differentially expressed genes (DEGs). 
Gene expression with log2 fold change ≥ 1 or ≤ − 1, and 
adjusted P-value < 0.01 was considered as differentially 
expressed. Universal Protein Resource (UniProt) (https 
://www.unipr ot.org/), Kyoto Encyclopedia of Genes and 
Genomes (KEGG) Orthology Based Annotation System 
3.0 (KOBAS) (http://kobas .cbi.pku.edu.cn/index .php) 
and Gene Ontology (GO, http://geneo ntolo gy.org/) were 
used for gene/protein functional annotation, pathway 
annotation and gene enrichment analyses, respectively. 
The GO enrichment analysis results were categorized 
according to the biological process (BP), cellular compo-
nent (CC) and molecular function (MF). The RNA-seq, 
reads alignment and DEG identification were carried out 
at BGI-Shenzhen, China.
Verification of RNA‑seq results by qPCR
Quantitative real-time PCR (qPCR) was used to verify 
the RNA-seq results. The expression levels for 15 DEGs 
were determined by qPCR using the same RNA samples 
that were used for the sequencing. The RNA samples 
were reverse-transcribed to single strand cDNA using the 
 PrimeScriptTM RT reagent Kit (TaKaRa, Dalian, China). 
Fifteen genes (nine host cell genes and six T. gondii genes) 
were randomly selected for qPCR verification and β-actin 
was used as the reference gene. All qPCR reactions were 
performed on the BIO-CFX96 system (Bio-Rad, Califor-
nia, USA) using SYBR Green  GoTaq® qPCR Master Mix 
(Promega, Beijing, China) following the manufacturer’s 
instructions. The primers used for qPCR are listed in the 
Additional file 1: Table S1. The selected genes were ana-
lyzed in triplicate. The qPCR cycling conditions included 
95 °C for 2 min followed by 40 cycles of 95 °C for 10 s, 58 
°C for 15 s, 72 °C for 40 s, and the temperatures of the 
melting curve analysis ranged from 72 to 95 °C. The  2−
ΔΔCq method was used to calculate the relative expression 
of each gene.
Results
We analyzed the global gene expression of T. gondii 
infecting PK-15 cells in the absence or presence of 0.1 
μM monensin treatment using an Illumina platform. The 
obtained sequences were aligned against pig and T. gondii 
genome sequences. More than 11.01 Gb of clean bases/
reads were obtained from each treated and untreated 
sample (Additional file 2: Table S2).
Differentially expressed genes (DEGs)
Three upregulated and 1012 downregulated T. gondii 
genes were detected at 6 h post-treatment, while 3856 
downregulated T. gondii genes were found at 24 h post-
treatment (Fig.  1). Interestingly, 990 downregulated T. 
gondii DEGs were shared between monensin-treated 
samples at 6 and 24 h (Fig. 2). These 990 downregulated 
Fig. 1 Distribution of the differently expressed genes (DEGs) of T. 
gondii across the examined groups. X‑axis shows the difference 
between treated and untreated samples, and at two different 
time points (6 h and 24 h post‑treatment). Y‑axis represents the 
number of DEGs. Red and blue colours represent upregulated and 
downregulated DEGs, respectively
Fig. 2 Venn diagram showing the overlap of the number of up and 
downregulated genes of T. gondii in C6 vs M6 group (6 h), and C24 vs 
M24 group (24 h)
Page 4 of 11Zhai et al. Parasites Vectors           (2020) 13:84 
genes accounted for 97.8% of the downregulated genes at 
6 h and 25.7% of the downregulated genes at 24 h post-
treatment. The expression of 15 genes obtained through 
RNA-seq were confirmed by qPCR and the validation 
results are shown in Fig. 3.
Gene Ontology (GO) analysis of the DEGs
A total of 44 GO terms, including 17 biological pro-
cess (BP) terms, 15 cellular component (CC) terms and 
12 molecular function (MF) terms were significantly 
enriched for 4871 T. gondii DEGs (Fig. 4). Among the BP 
category at 6 and 24 h, the top two enriched GO terms 
were metabolic process and cellular process. In the CC 
category at 6 h, membrane and cell were the top two GO 
terms (Fig.  4a), while membrane and membrane part 
were the top two GO terms at 24 h (Fig. 4b). In the MF 
category at 6 and 24 h, the top two GO terms were cata-
lytic activity and binding.
KEGG pathway analysis
We also mapped the DEGs to six different KEGG sub-
systems, including metabolism, genetic information 
processing, environmental information processing, cel-
lular processes, organismal systems and human diseases 
(Fig.  5). KEGG pathway analysis also showed that most 
of T. gondii DEGs were enriched in infectious diseases, 
signal transduction and translation. The 30 most signifi-
cantly enriched pathways are shown in Fig.  6; spliceo-
some, ribosome, and protein processing in endoplasmic 
reticulum are the top three significantly enriched path-
ways in T. gondii (Additional file 3: Figure S1, Additional 
file 4: Figure S2, Additional file 5: Figure S3).
Transcription factors (TFs) of DEGs
TFs are key regulators of gene expression [24]. They bind 
to specific DNA sequences and activate or repress gene 
expression by DNA-binding domains (DBDs) [25]. Based 
on their DBDs, TFs can be classified into different families 
[26]. In our study, differentially expressed TFs were classi-
fied into 25 families (Fig. 7), and homeobox and zf-C2H2 
were the two most significantly enriched TFs in T. gondii.
Protein–protein interaction (PPI) of DEGs
Using the String database prediction, PPI networks of 
T. gondii with a combined score > 980 at 6 h post-mon-
ensin treatment are shown in Fig.  8. TGME49_002580 
(XM_018779214.1), which encodes ATPases associated 
with diverse cellular activities (AAA proteins), was the 
most enriched upregulated gene in T. gondii. Four pro-
teins, TGME49_238180 (XM_018780522.1, K03037), 
TGME49_292220 (XM_002368522.2, K03033), 
TGME49_250830 (XM_018780938.1, K03031) and 
TGME49_227960 (XM_002366378.2, K03036), 
formed a separate mutual network. TGME49_238180, 
TGME49_292220 and TGME49_227960 regulate 
TGME49_250830, while TGME49_292220 regulates 
TGME49_250830, TGME49_227960 and TGME49_238180. 
These proteins (TGME49_292220 (K03033, Rpn3), 
TGME49_238180 (K030037, Rpn7), TGME49_227960 
(K03036, Rpn6), and TGME49_250830 (K03031, Rpn12)) are 
the components of the 19S regulatory particle in the protea-
some pathway (map03050, Additional file 6: Figure S4). The 
protein TGME49_289830 (XM_002368367.1, K03246) regu-
lates two proteins, TGME49_294670 (XM_002370195.2, 
K03248) and TGME49_317720 (XM_018782917.1, K03251); 
where they all belong to the family of translation initia-
tion factors (eIF3) of the RNA transport pathway. Addi-
tional file  7: Figure S5 shows T. gondii PPIs at 24 h where 
TGME49_210790 (XM_002371193.2), TGME49_266460 
(XM_002368694.2), TGME49_297140 (XM_018782303.1), 
TGME49_275750 (XM_002371561.2) and TGME49_305010 
(XM_002370254.1) are some of the proteins that warrant 
further studies.
Fig. 3 Verification of the RNA‑seq data by using qPCR. Bars represent the mean fold changes of the expression of six T. gondii genes and nine 
porcine genes
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Fig. 4 GO enrichment analysis of the differentially expressed genes (DEGs) of T. gondii. The bar graphs show the number of T. gondii DEGs enriched 
in GO terms belonging to the three GO categories, biological process, cellular component and molecular function, at 6 h (a) and 24 h (b). X‑axis 
represents the GO terms and Y‑axis represents the number of upregulated (Up) and downregulated (Down) genes in different GO terms
Page 6 of 11Zhai et al. Parasites Vectors           (2020) 13:84 
Discussion
The search for new anti-Toxoplasma gondii drugs has 
been active for several decades [12, 13], but only a few 
drugs are currently approved for use in humans [1, 27]. 
Although sulfa drugs can be effectively used for the 
prevention and control of T. gondii infection in humans 
and animals, their side effects should not be ignored [28]. 
Compared to the mainstream anti-Toxoplasma drugs 
(sulfa and ethylamines, trimethoprim combined with sul-
famethoxazole), monensin seems to be less cytotoxic [29, 
Fig. 5 KEGG annotation of the DEGs in the transcriptome of T. gondii. X‑axis label represents the number of DEGs in the corresponding KEGG 
pathways in each KEGG subsystem. Y‑axis label represents main clusters of the KEGG pathways
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30]. The anticoccidial drug monensin has been shown to 
inhibit the viability and even damage the bradyzoite stage 
of T. gondii [29] and to prevent the shedding of oocysts 
from cats [31]. Monensin can also induce cell cycle arrest 
and autophagy, leading to death of T. gondii tachyzoites 
[32, 33], probably mediated by an oxidative stress-related 
mechanism [14]. Despite this body of literature describ-
ing the mechanisms that mediate the inhibitory effects of 
monensin against different life-cycle forms of T. gondii, 
the comprehensive mechanisms responsible for killing of 
T. gondii by monensin remains incompletely defined.
In this study, we used RNA-seq technology to identify 
the global transcriptomic changes in T. gondii caused 
by monensin treatment. We found 4868 downregulated 
genes and three upregulated genes in T. gondii follow-
ing monensin treatment. The significant number of 
Fig. 6 Scatterplot of the top 30 most enriched KEGG pathways of T. gondii. Y‑axis label represents the distinct KEGG pathways, and X‑axis label 
represents the Rich Factor. Rich Factor refers to the ratio of DEGs annotated in the pathway to total number of genes annotated in the pathway. 
The greater the Rich Factor, the greater the degree of pathway enrichment. Dot size represents the number of DEGs (bigger dots denote large DEG 
number and vice versa). The colours of the dots represent the P‑values of enrichment. Red colour indicates high enrichment, while green colour 
indicates low enrichment
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downregulated genes shows the overwhelming impact of 
monensin treatment on T. gondii, especially at 24 h post-
treatment. We also performed GO enrichment analysis 
to analyze the significantly altered biological processes in 
T. gondii caused by monensin treatment. The two most 
significantly enriched BP GO terms at 6 and 24 h were 
metabolic process and cellular process. In the MF cat-
egory, the top two GO terms were catalytic activity and 
binding at 6 and 24  h. For the CC category, membrane 
and membrane parts were the two most enriched GO 
terms at both 6 and 24 h (Fig.  4); these included mem-
brane components that contribute to material transpor-
tation, membrane integration, environmental resistance 
and various biological functions that are essential for 
cell survival. These findings indicate that anti-T. gondii 
effects of monensin could be mediated by impairment 
of most of T. gondii biological processes and membrane 
components.
KEGG pathway analysis showed that spliceosome, 
ribosome and protein processing in the endoplasmic 
reticulum were the top three of the 30 most significantly 
enriched pathways in T. gondii (Fig. 6). Protein process-
ing in the endoplasmic reticulum is a pathway that influ-
ences protein folding in the endoplasmic reticulum [34]. 
Proteolytic cleavage of effectors in the endoplasmic 
reticulum pathway is essential for the survival of T. gondii 
[35]. Additional file  5: Figure S3 shows that most genes 
involved in protein processing in the endoplasmic retic-
ulum pathway are downregulated. Thus, we infer that 
monensin could suppress protein processing in the endo-
plasmic reticulum pathway in T. gondii, which would 
contribute to its anti-T. gondii activity.
The spliceosomes are RNA-protein complexes respon-
sible for removal of introns (non-coding segments) 
from pre-messenger RNAs to form mature mRNAs in 
a process known as splicing [36]. Spliceosome compo-
nents have been identified in T. gondii [37]. Our analy-
sis showed that all DEGs involved in the spliceosome 
pathway are downregulated by monensin (Additional 
file  3: Figure S1). Ribosome biogenesis is closely related 
to multiple cellular signaling pathways and any defects in 
ribosome production can cause many diseases, and even 
death [38]. The ribosome profiling at the level of tran-
scription and translation of T. gondii has been reported 
[39]. However, how the ribosome of T. gondii is altered 
by monensin remains unknown. Our analysis showed 
that DEGs involved in ribosome biogenesis are signifi-
cantly downregulated by monensin (Additional file 4: Fig-
ure S2). These findings indicate that monensin can also 
interfere with genes involved in mRNA translation and 
ribosome biogenesis, which can restrict the growth of T. 
gondii.
The biogenesis of the spliceosome and ribosome are 
regulated by transcription factors (TFs). We found that 
homeobox and zf-C2H2 were the two most significantly 
enriched TFs (Fig.  7). The homeobox TF regulates the 
expression of genes associated with various developmen-
tal processes in animals, fungi and plants [40]. The zf-
C2H2 TF family contains a small protein structural motif, 
the zinc finger (zf ), which coordinates one or more zinc 
ions (Zn2+) [41]. TFs containing zinc fingers have been 
implicated in a variety of biological processes in T. gondii 
[42, 43]. For example, depletion of TgZNF2 in T. gondii 
caused an arrest of the parasite growth at the G1 phase of 
the cell cycle and accumulation of poly(A) RNA in their 
nucleus [43]. Thus, monensin-induced downregulation 
Fig. 7 Classification of the differentially expressed TFs. The X‑axis 
label represents the number of genes and the Y‑axis label represents 
the transcription factor family names
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of these two TFs, homeobox and zf-C2H2, may disrupt 
the growth and development of T. gondii, further eluci-
dating more aspects of monensin mode of action against 
T. gondii.
The PPI analysis revealed several proteins that 
were downregulated by monensin, including 
TGME49_210790, TGME49_305010, TGME49_266460 
and TGME49_002580. TGME49_002580 is ATPase, 
AAA family protein, which plays critical roles in 
various cellular processes [44]. TGME49_210790 
(XM_002371193.2) encodes a putative dihydrooro-
tate dehydrogenase (DHODH), which mediates the 
fourth step of de novo pyrimidine biosynthesis [45]. 
In T. gondii, disruption of de novo pyrimidine syn-
thesis results in uracil auxotrophy, virulence attenu-
ation and inability to establish latent infection [46]. 
Inhibition of the activity of T. gondii dihydroorotate 
dehydrogenase (TgDHODH) can potentiate the growth 
inhibiting potential of 1-hydroxyquinolones in T. gon-
dii [45]. TGME49_305010 (XM_002370254.1) is puta-
tively encoded as pre-mRNA branch site protein p14, 
which is associated with U2 small nuclear ribonu-
cleoprotein particles (snRNPs) and participates in the 
spliceosome (map03040) pathway. TGME49_266460 
(XM_002368694.2) encodes a small ubiquitin-like fam-
ily modifier (SUMO) belonging to the Ubl family, while 
only one gene is encoded by SUMO in lower eukary-
otes, including T. gondii [47]. A previous study of T. 
gondii SUMO proteomics revealed over 100 sumoylated 
proteins involved in translation, metabolism, post-
translational modification, and protein degradation 
[48]. Altering these proteins in T. gondii may be lethal, 
which would then contribute to the anti-T. gondii activ-
ity of monensin.
Fig. 8 Transcriptional regulatory network analysis of Toxoplasma gondii. Protein–protein interaction (PPI) networks of DEGs of T. gondii at 6 h. The 
red and green dots denote the upregulated and downregulated genes, respectively
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Conclusions
This study examined the transcriptomic landscape of 
T. gondii infecting PK-15 cells treated with monensin 
and identified monensin-induced DEGs in T. gondii. 
Our genome-wide transcriptional analysis revealed that 
4868 T. gondii genes were downregulated in treated 
cell cultures, suggesting that monensin can suppress 
the expression of the majority of T. gondii genes. Also, 
monensin treatment appears to adversely influence 
various crucial metabolic and cellular processes of T. 
gondii, such as spliceosome, ribosome and protein pro-
cessing in the endoplasmic reticulum. Additionally, 
monensin induced downregulation of two transcription 
factors, homeobox and zf-C2H2, in T. gondii. Further 
analysis of the identified transcriptional changes can 
provide useful information for better understanding of 
the mechanism of action of monensin against T. gondii.
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